1.09%
1.57%
-7.56%
-4.42%
-1.52%
-10.99%
46.61%
AI Spotlight on VIRP
Company Description
Virbac SA manufactures and sells a range of products and services for companion and food-producing animals in France, Europe, Latin America, North America, the Asia Pacific, the Middle East, and Africa.The company offers a range of vaccines, dental hygiene, reproduction, dermatology, parasiticides, diagnostic, antibiotics, and aquaculture products; and veterinary medicines for anesthesia, geriatrics, behavior, and injectable micronutrients, as well as petfood and electronic identification.It serves veterinarians, farmers, and pet owners.
Virbac SA was founded in 1968 and is headquartered in Carros, France.
Market Data
| Last Price | 324 |
| Change Percentage | 1.09% |
| Open | 325 |
| Previous Close | 320.5 |
| Market Cap ( Millions) | 2692 |
| Volume | 4235 |
| Year High | 400 |
| Year Low | 302 |
| M A 50 | 317.01 |
| M A 200 | 344.83 |
Financial Ratios
| FCF Yield | 3.39% |
| Dividend Yield | 0.41% |
| ROE | 14.88% |
| Debt / Equity | 40.94% |
| Net Debt / EBIDTA | 94.56% |
| Price To Book | 2.73 |
| Price Earnings Ratio | 19.25 |
| Price To FCF | 29.49 |
| Price To sales | 2.01 |
| EV / EBITDA | 11.12 |
News
- Jan -16 - Virbac: Strong annual revenue growth of +13.6% supported by dynamic organic growth (+7.5%) and the strategic contribution of our acquisitions (+6.1%)
- Dec -03 - Virbac: Türkiye: Virbac acquires its companion animal distributor
- Nov -10 - Virbac (ENXTPA:VIRP) Raises 2024 Earnings Guidance, Eyes Growth with Acquisitions and Market Expansion
- Oct -17 - Virbac: Strong revenue growth as of the end of September at +12.6% and +8.6% at constant exchange rates and scope. 2024 targets maintained.
- Sep -17 - Virbac SA (FRA:V16) (Q2 2024) Earnings Call Transcript Highlights: Strong Organic Growth and ...
- Sep -16 - Virbac: erratum short Press release Capital reduction_September 13, 2024
- Sep -13 - Virbac: Information on the departure of Sébastien Huron
- Sep -13 - Virbac 2024 half-year results
- Sep -13 - Virbac : the board of directors announces a capital reduction through cancellation of treasury shares
- Jul -16 - VIRBAC: exceptional first-half momentum (+16.2% at constant exchange rates) driven by all regions
- Jul -11 - Virbac: Termination of the liquidity contract
- Jul -08 - VIRBAC announces executive management changes
- Jul -02 - Virbac finalizes minority shares’ acquisition of Globion, an Indian poultry vaccines specialist
- Apr -16 - VIRBAC: Building on the momentum of the second half of 2023, strong first-quarter revenue growth of +10.8% at constant exchange rates
- Apr -09 - Virbac : Declaration of the number of shares and voting rights 03/2024
- Apr -02 - Virbac acquired Sasaeah, a leading animal health player in Japan
- Mar -19 - VIRBAC: 2023 ANNUAL RESULTS
- Mar -06 - Virbac to take a leading position in Japan through the acquisition of Sasaeah
- Jan -17 - VIRBAC: Annual revenue growth of +4.9% thanks to record fourth-quarter activity at +11.5%
- Dec -19 - Outlook 2023-2024
Business Breakdown
Expected Mid-Term Growth
Segment n°1 -> Farm Animals - Other Ruminants
Expected Growth : 5 %
What the company do ?
Farm Animals - Other Ruminants from Virbac SA refers to a range of products for the health and well-being of non-traditional ruminant species such as deer, elk, and bison.
Why we expect these perspectives ?
Virbac SA's 5% growth in Farm Animals - Other Ruminants is driven by increasing demand for parasiticides and vaccines, expansion into emerging markets, and strategic partnerships. Growing awareness of animal health and welfare, coupled with rising meat consumption, also contribute to this growth. Additionally, the company's focus on innovation and R&D investments in novel products and services supports its market share expansion.
Segment n°2 -> Companion Animals - Specialties
Expected Growth : 4 %
What the company do ?
Companion Animals - Specialties from Virbac SA provides veterinary care solutions for pets, focusing on dermatology, nutrition, and hygiene products.
Why we expect these perspectives ?
Virbac SA's Companion Animals - Specialties segment growth is driven by increasing pet humanization, rising demand for premium pet care, and growing awareness of animal health. Additionally, advancements in veterinary medicine, expansion into emerging markets, and strategic partnerships contribute to the segment's growth.
Segment n°3 -> Companion Animals - Specialized Petfood
Expected Growth : 5 %
What the company do ?
Companion Animals - Specialized Petfood from Virbac SA offers tailored nutrition for cats and dogs, addressing specific health needs and lifestyles.
Why we expect these perspectives ?
Strong demand for premium petfood, increasing pet humanization, and rising awareness of animal health drive growth. Virbac's specialized petfood offerings cater to specific dietary needs, attracting pet owners willing to pay a premium. Expanding distribution channels, strategic partnerships, and innovative products further fuel growth.
Segment n°4 -> Companion Animals - Others
Expected Growth : 3 %
What the company do ?
Companion Animals - Others from Virbac SA refers to a range of products for pets, excluding dogs and cats, such as horses, birds, and small mammals.
Why we expect these perspectives ?
Virbac SA's Companion Animals - Others segment growth is driven by increasing pet humanization, rising demand for premium pet care, and growing awareness of animal health. Additionally, the company's strategic expansion into emerging markets and innovative product offerings contribute to its growth.
Segment n°5 -> Companion Animals - Parasiticides
Expected Growth : 6 %
What the company do ?
Companion Animals - Parasiticides from Virbac SA: Products to prevent and treat internal and external parasites in pets, such as fleas, ticks, and worms.
Why we expect these perspectives ?
The 6% growth of Companion Animals - Parasiticides from Virbac SA is driven by increasing pet ownership, rising awareness of parasitic diseases, and growing demand for convenient and effective treatments. Additionally, the expansion of veterinary clinics and online sales channels, as well as the introduction of new products with improved efficacy, contribute to the segment's growth.
Segment n°6 -> Companion Animals - Antibiotics/Dermatology
Expected Growth : 5 %
What the company do ?
Companion Animals - Antibiotics/Dermatology from Virbac SA: Products for treating skin infections and promoting skin health in companion animals.
Why we expect these perspectives ?
Strong demand for pet care, increasing pet ownership, and rising awareness of animal health drive growth in Companion Animals - Antibiotics/Dermatology segment. Virbac SA's product portfolio expansion, strategic partnerships, and geographic presence in high-growth markets also contribute to the 5% growth.
Segment n°7 -> Farm Animals - Bovine Antibiotics
Expected Growth : 4 %
What the company do ?
Farm Animals - Bovine Antibiotics from Virbac SA refers to a range of antibiotics specifically designed for cattle, helping to treat and prevent bacterial infections in bovine species.
Why we expect these perspectives ?
The 4% growth of Bovine Antibiotics from Virbac SA is driven by increasing demand for animal health products, rising awareness of antibiotic resistance, and growing adoption of veterinary care in emerging markets. Additionally, the company's strong R&D pipeline and strategic partnerships contribute to its market share expansion.
Segment n°8 -> Companion Animals - Immunology
Expected Growth : 7 %
What the company do ?
Companion Animals - Immunology from Virbac SA: Develops and commercializes vaccines and diagnostic tools for companion animals, enhancing their health and well-being.
Why we expect these perspectives ?
Strong demand for pet healthcare, increasing pet humanization, and rising awareness of zoonotic diseases drive growth in Companion Animals - Immunology segment. Virbac SA's innovative vaccine portfolio, strategic partnerships, and expanding distribution network further support the 7% growth rate.
Segment n°9 -> Farm Animals - Bovine Parasiticides
Expected Growth : 6 %
What the company do ?
Farm Animals - Bovine Parasiticides from Virbac SA are products used to prevent and treat internal and external parasites in cattle, promoting healthy livestock.
Why we expect these perspectives ?
The 6% growth of Farm Animals - Bovine Parasiticides from Virbac SA is driven by increasing demand for animal health products, rising awareness of parasitic diseases, and growing adoption of preventive measures in livestock farming. Additionally, expansion into emerging markets and product innovation are contributing to the segment's growth.
Segment n°10 -> Farm Animals - Other Pig/Poultry
Expected Growth : 4 %
What the company do ?
Farm Animals - Other Pig/Poultry from Virbac SA refers to a range of products and services for the health and well-being of pigs and poultry, excluding vaccines.
Why we expect these perspectives ?
Virbac SA's Farm Animals - Other Pig/Poultry segment growth is driven by increasing demand for animal health products, expansion into emerging markets, and strategic partnerships. Rising consumer awareness of animal welfare and disease prevention also contribute to growth. Additionally, the company's focus on innovation and R&D investments in vaccine development and parasiticide products further support segment growth.
Segment n°11 -> Farm Animals - Aquaculture
Expected Growth : 5 %
What the company do ?
Farm Animals - Aquaculture from Virbac SA refers to the segment of animal health products and services for aquatic species, such as fish and shrimp, to prevent and treat diseases.
Why we expect these perspectives ?
Virbac SA's 5% growth in Farm Animals - Aquaculture is driven by increasing global demand for protein-rich food, rising aquaculture production, and growing adoption of sustainable farming practices. Additionally, advancements in animal health products and services, such as vaccination and parasite control, contribute to the segment's growth.
Segment n°12 -> Companion Animals - Equine
Expected Growth : 4 %
What the company do ?
Companion Animals - Equine from Virbac SA provides veterinary care products for horses, focusing on parasiticides, vaccines, and dental care.
Why we expect these perspectives ?
Virbac SA's Companion Animals - Equine segment growth is driven by increasing pet ownership, rising disposable income, and growing awareness of animal health. The equine market is further boosted by the growing popularity of horse riding and equestrian sports, leading to increased demand for veterinary care and products.
Segment n°13 -> Other
Expected Growth : 3 %
What the company do ?
Virbac SA's 'Other' segment includes sales from various products and services not classified under their core business, such as pet food and diagnostic products.
Why we expect these perspectives ?
Virbac SA's 3% growth in the 'Other' segment is driven by increasing demand for pet accessories and supplies, expansion into new markets, and strategic partnerships. Additionally, the company's focus on innovation and R&D has led to the development of new products, further contributing to growth.
Segment n°14 -> Farm Animals - Pig/Poultry Antibiotics
Expected Growth : 5 %
What the company do ?
Farm Animals - Pig/Poultry Antibiotics from Virbac SA refers to a range of antibiotic products for pigs and poultry, helping to prevent and treat bacterial infections in farm animals.
Why we expect these perspectives ?
Strong demand for animal health products, increasing adoption of antibiotics in pig and poultry farming, growing concerns over animal welfare, and rising prevalence of diseases in livestock drive the 5% growth of Virbac SA's farm animals antibiotics segment.
Virbac Sa Products
| Product Range | What is it ? |
|---|---|
| Vaccines | Virbac SA offers a range of vaccines for companion animals, including dogs, cats, and horses, to protect against various diseases. |
| Parasiticides | Virbac SA provides a variety of parasiticides to control internal and external parasites in animals, including flea and tick preventatives. |
| Dermatology Products | Virbac SA offers a range of products to treat skin conditions in animals, including shampoos, conditioners, and topical treatments. |
| Dental Products | Virbac SA provides dental care products, including toothpaste, dental chews, and water additives, to promote oral health in animals. |
| Nutrition and Supplements | Virbac SA offers a range of nutritional supplements and specialty foods to support animal health and well-being. |
| Reproduction and Breeding Products | Virbac SA provides products to support reproductive health in animals, including breeding and fertility management. |
Virbac SA's Porter Forces
Threat Of Substitutes
The threat of substitutes for Virbac SA is medium, as there are some alternative products available in the market, but they are not highly attractive to customers.
Bargaining Power Of Customers
The bargaining power of customers for Virbac SA is low, as the company has a strong brand presence and customers are loyal to its products.
Bargaining Power Of Suppliers
The bargaining power of suppliers for Virbac SA is medium, as the company has a diverse supplier base, but some suppliers have a higher bargaining power due to their size and importance.
Threat Of New Entrants
The threat of new entrants for Virbac SA is low, as the company has a strong market presence and high barriers to entry in the animal health industry.
Intensity Of Rivalry
The intensity of rivalry for Virbac SA is high, as the company operates in a highly competitive market with several established players.
Capital Structure
| Value | |
|---|---|
| Debt Weight | 9.66% |
| Debt Cost | 8.43% |
| Equity Weight | 90.34% |
| Equity Cost | 8.43% |
| WACC | 8.43% |
| Leverage | 10.69% |
Virbac SA : Quality Control
Virbac SA passed 6 out of 9 key points:
Historical Valuation
Price/Earnings Ratio
Margin Valuation
Peers Valuation
Competitors
| Company | Rational |
|---|---|
| IPN.PA | Ipsen S.A. operates as a biopharmaceutical company worldwide. The company provides drugs in the areas of oncology, neuroscience, gastroenterology, cognitive disorders, and rare diseases. It offers Somatuline for neuroendocrine tumors … |
| ORNAV.HE | Orion Oyj develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients (APIs) in Finland, Scandinavia, other European countries, North America, and internationally. It provides prescription drugs and … |
| REC.MI | Recordati Industria Chimica e Farmaceutica S.p.A., together with its subsidiaries, engages in the research, development, manufacture, marketing, and sale of pharmaceuticals worldwide. The company offers pharmaceuticals in various therapeutic areas, … |
| ROVI.MC | Laboratorios Farmaceuticos Rovi, S.A. engages in the research, development, production, and sale of pharmaceutical products in Spain, European Union, OECD countries, and internationally. The company distributes other products that are … |
| NOVN.SW | Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and … |
Peers Metrics
DCF BETA
Expected Cash-Flows
Scoring Insights
Peers Group Analysis
🥇
Novartis
A-Score
1-Year Total Return ->
🥈
Ipsen
A-Score
1-Year Total Return ->
🥉
Recordati
A-Score
1-Year Total Return ->
4
Orion
A-Score
1-Year Total Return ->
5
Rovi
A-Score
1-Year Total Return ->
6
